These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11720635)

  • 41. Nisoldipine: a new dihydropyridine calcium-channel blocker.
    Mitchell J; Frishman W; Heiman M
    J Clin Pharmacol; 1993 Jan; 33(1):46-52. PubMed ID: 8429113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
    Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J
    Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What does nisoldipine coat core (CC) add to current therapy that is clinically meaningful?
    Opie LH
    Am J Cardiol; 1997 May; 79(10A):29-32; discussion 47-8. PubMed ID: 9186064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy of angina pectoris].
    Sterz H
    Wien Med Wochenschr; 1984 Dec; 134(23-24):534-9. PubMed ID: 6152089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcium channel blockers in treatment of hypertension.
    Muntwyler J; Follath F
    Prog Cardiovasc Dis; 2001; 44(3):207-16. PubMed ID: 11727278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nisoldipine CC: clinical experience in ischaemic heart disease.
    Melcher A; Dens J; Curry P; Hagel H
    Cardiology; 1997; 88 Suppl 1():17-23; discussion 24-5. PubMed ID: 9118164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.
    Kumar S; Hall RJ
    Drugs Aging; 2003; 20(11):805-15. PubMed ID: 12964887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical pharmacokinetics of nisoldipine coat-core.
    Heinig R
    Clin Pharmacokinet; 1998 Sep; 35(3):191-208. PubMed ID: 9784933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
    Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
    Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of hypertension from volume to vasoconstriction: The ACE up your sleeve.
    Stanley JC; Samson RH
    Semin Vasc Surg; 2002 Dec; 15(4):225-36. PubMed ID: 12478497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group.
    Van der Vring JA; Cleophas TJ; Van der Wall EE; Niemeyer MG
    Am J Ther; 1999 Jul; 6(4):229-33. PubMed ID: 11329102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
    Todd PA; Faulds D
    Drugs; 1992 Aug; 44(2):251-77. PubMed ID: 1382018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Once-a-day calcium antagonist for antianginal and antihypertensive therapy.
    Bühler FR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 7():S1-2. PubMed ID: 2467115
    [No Abstract]   [Full Text] [Related]  

  • 60. Correlation between predicted theoretical mechanistic biochemistry (TMB) data and therapeutic effects in the management of vascular disorders with calcium channel blockers.
    Akintonwa DA; Odigwe CO
    Med Hypotheses; 2000 Jun; 54(6):944-7. PubMed ID: 10867744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.